GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The etiology of schizophrenia remains unclear In recent one decade, hypofunction of
N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of
schizophrenia. Hence, enhancing NMDA neurotransmission was considered as a new approach for
schizophrenia treatment.
To date, refractory schizophrenia (particularly clozapine-resistant) is still a difficult
clinical issue. However, the effect of NMDA treatment in refractory schizophrenia is still
unknown. Therefore, the primary goal of this study is to investigate the efficacy and safety
of NMDA adjuvant therapy in refractory schizophrenia, and to identify the predictors for
treatment response to NMDA enhancers.